Study of mavacamten treatment for hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow).
- Started taking mavacamten for the first time between October 24, 2024 and March 31, 2026.
- At least 18 years old when you started taking the medicine.
- Had at least two doctor visits or other health records after starting the medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study looks at whether adjusting the dose of mavacamten based on heart function helps people with obstructive hypertrophic cardiomyopathy feel better and have fewer side effects. It is for people who are already on mavacamten and want to see if a personalized dose approach works.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
This study collects blood samples and medical information from people with obstructive hypertrophic cardiomyopathy to learn why the medication mavacamten works differently in different people. The goal is to understand how genes and other factors influence treatment response, which may help personalize care.
This study looks at whether people with hypertrophic cardiomyopathy who are doing well on mavacamten can slowly reduce or stop their beta-blocker medication. The goal is to find out if it's safe and helps patients manage with fewer medications.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
Hear when a new Obstructive Hypertrophic Cardiomyopathy (oHCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.